Paul Schmidt is a trial lawyer who has led the defense of some of the most complex litigations nationwide.
Mr. Schmidt was cited by the National Law Journal in its "Top Litigators Share Winning Strategies" feature (11/2/2015). His wins have been recognized by American Lawyer (Product Liability Litigation Department of the Year and "Covington Lawyers Kill on Cross-Exams in Cymbalta Case"), National Law Journal (recognizing Covington as Washington Litigation Department of the Year finalist), and Law360 ("Roche Still Perfect In Accutane Appeals with Defiant Tactic"). According to Chambers USA, he "continues to impress sources with his successful track record in pharmaceutical litigation and appeals" and is "an exceedingly bright lawyer."
Mr. Schmidt’s recent trial work includes serving as lead trial counsel for Cymbalta, securing three trial wins for Lilly; securing favorable outcomes as trial counsel for Hoffmann-La Roche Inc. in several extended jury trials; serving as trial counsel for the National Football League in trials involving complex labor and commercial disputes as well as television carriage disputes; and representing Genentech in a first-of-its-kind FDA hearing over the withdrawal of accelerated approval for a medication. He also served as Lead Counsel for Boehringer Ingelheim in the Pradaxa multidistrict litigation.
Mr. Schmidt has also successfully argued appeals before state and federal courts around the country, obtaining wins that have been recognized by the National Law Journal in its Appellate Hot List. These wins have included several rulings for Hoffmann-La Roche Inc. dismissing claims that acne drug Accutane causes depression, birth defects, and suicide.